| House Positions for C:MDNA from 20210120 to 20210120 |
| House | Bought | $Val | Ave | Sold | $Val | Ave | Net | $Net |
|---|---|---|---|---|---|---|---|---|
| 79 CIBC | 55,631 | 306,455 | 5.509 | 18,500 | 101,499 | 5.486 | 37,131 | -204,956 |
| 5 Penson | 4,435 | 23,800 | 5.366 | 2,600 | 14,147 | 5.441 | 1,835 | -9,653 |
| 80 National Bank | 2,501 | 13,492 | 5.395 | 1,880 | 10,285 | 5.471 | 621 | -3,207 |
| 72 Credit Suisse | 400 | 2,214 | 5.535 | 0 | 400 | -2,214 | ||
| 13 Instinet | 300 | 1,680 | 5.60 | 0 | 300 | -1,680 | ||
| 85 Scotia | 236 | 1,244 | 5.271 | 0 | 236 | -1,244 | ||
| 74 GMP | 2,000 | 10,500 | 5.25 | 1,800 | 9,990 | 5.55 | 200 | -510 |
| 39 Merrill Lynch | 900 | 4,866 | 5.407 | 700 | 3,915 | 5.593 | 200 | -951 |
| 212 Virtu | 155 | 827 | 5.335 | 0 | 155 | -827 | ||
| 14 ITG | 0 | 179 | 931 | 5.201 | -179 | 931 | ||
| 53 Morgan Stanley | 480 | 2,551 | 5.315 | 1,200 | 6,802 | 5.668 | -720 | 4,251 |
| 91 Jones | 0 | 1,000 | 5,558 | 5.558 | -1,000 | 5,558 | ||
| 33 Canaccord | 0 | 1,200 | 6,720 | 5.60 | -1,200 | 6,720 | ||
| 2 RBC | 223 | 1,266 | 5.677 | 3,246 | 17,456 | 5.378 | -3,023 | 16,190 |
| 1 Anonymous | 15,306 | 83,820 | 5.476 | 22,320 | 122,263 | 5.478 | -7,014 | 38,443 |
| 89 Raymond James | 0 | 9,900 | 53,460 | 5.40 | -9,900 | 53,460 | ||
| 7 TD Sec | 11,390 | 60,830 | 5.341 | 29,432 | 160,518 | 5.454 | -18,042 | 99,688 |
| TOTAL | 93,957 | 513,545 | 5.466 | 93,957 | 513,544 | 5.466 | 0 | -1 |
News
In company news, Moderna (MRNA) publishing late-stage data confirming the efficacy and safety of its mRNA-1273 vaccine candidate, with the messenger RNA-based vaccine preventing COVID-19 in 94.1% of the trial participants receiving the two-dose regimen 28 days apart. Of the nearly 30,000 volunteers participating in the study, only 11 of the 196 cases of COVID-19 were in the active group, according to the trial results published in the New England Journal of Medicine. US regulators approved emergency use of mRNA-1273 earlier this month.
Medicenna Therapeutics (MDNA) the Canadian immuno-oncology firm announced an at-the-market offering of up to $25 million of its common shares from time to time. Net proceeds will be used for general corporate purposes, including working capital, research and development, and clinical trial costs, the company said.
On January 6, 2021, Fahar Merchant, President and Chief Executive Officer of Medicenna Therapeutics Corp. ("Medicenna"), purchased an aggregate of 10,000 common shares of Medicenna (the "Shares") through the facilities of the Toronto Stock Exchange at prices ranging from $5.13 to $5.18, for an aggregate consideration of $51,778 (the "Transaction").
Prior to the Transaction, (i) Dr. Merchant beneficially owned an aggregate of 5,250,000 Shares, options ("Option") to purchase an aggregate of 1,377,299 Shares and 100,000 common share purchase warrants exercisable at a price of $1.20 per Share until December 21, 2023 (the "Warrants"); (ii) Ms. Rosemina Merchant, a joint actor with Dr. Merchant, beneficially owned 5,250,000 Shares, Options to purchase 834,637 Shares and 100,000 Warrants; and (iii) Aries Biologics Inc. ("Aries") an entity jointly-owned by Dr. Merchant and Ms. Merchant, beneficially owned an aggregate of 5,500,000 Shares. Together, Dr. Merchant and Ms. Merchant beneficially owned, directly and through Aries, an aggregate of 16,000,000 Shares, 2,211,936 Options and 200,000 Warrants, representing 31.68% of the currently issued and outstanding Shares on a non-diluted basis, and 34.79% of the currently issued and outstanding Shares on a partially-diluted basis, assuming exercise of the Options and Warrants held by Dr. Merchant and Ms. Merchant only.
Following the Transaction, (i) Dr. Merchant beneficially owns an aggregate of 5,260,000 Shares, Options to purchase an aggregate of 1,377,299 Shares and 100,000 Warrants; (ii) Ms. Rosemina Merchant beneficially owns 5,250,000 Shares, Options to purchase 834,637 Shares and 100,000 Warrants; and (iii) Aries beneficially owns an aggregate of 5,500,000 Shares. Together, Dr. Merchant and Ms. Merchant beneficially own, directly and through Aries, an aggregate of 16,010,000 Shares, 2,211,936 Options and 200,000 Warrants, representing 31.70% of the currently issued and outstanding Shares on a non-diluted basis, and 34.81% of the currently issued and outstanding Shares on a partially-diluted basis, assuming exercise of the Options and Warrants held by Dr. Merchant and Ms. Merchant only.
Dr. Merchant and Ms. Merchant, as Medicenna's President and Chief Executive Officer and Chief Development Officer, respectively, in addition to together being Medicenna's largest shareholders, have been and will continue to be actively involved in the business, operations and strategic planning for Medicenna. The Shares beneficially owned by Dr. Merchant and Ms. Merchant, directly and through Aries, are held for investment purposes. Each of them intends to review on a continuing basis his or her investment in Medicenna and may, depending on market and other conditions, increase or decrease his or her beneficial ownership of securities of Medicenna through market transactions, private agreements, public offerings or otherwise.
Dr. Merchant relied on the normal course purchase exemption from the take-over bid rules contained in Section 4.1 of National Instrument 62-104 - Take-Over Bids and Issuer Bids with regards to the Transaction.
An early warning report relating to this transaction will be filed on SEDAR under Medicenna's profile at www.sedar.com. To obtain a copy of such report, please contact Ms. Elizabeth Williams, Chief Financial Officer of Medicenna at 416-648-5555. Medicenna's head office is located at 2 Bloor Street W., 7(th) Floor, Toronto, ON, M4W 3E2. Dr. Merchant's mailing address is 2 Bloor Street W., 7(th) Floor, Toronto, ON, M4W 3E2.
SOURCE Fahar Merchant
View original content: http://www.newswire.ca/en/releases/archive/January2021/07/c5430.html
SOURCE: Fahar Merchant
News
2020-12-30 18:20 ET - News Release
Ms. Elizabeth Williams reports
MEDICENNA ESTABLISHES AT-THE-MARKET SALES FACILITY
Medicenna Therapeutics Corp. has entered into a sales agreement with SVB Leerink acting as sales agent, pursuant to which the company may, from time to time sell, through "at-the-market" offerings on the Nasdaq Capital Market such number of common shares as would have an aggregate offering price of up to $25-million (U.S.) under the ATM prospectus supplement (as defined below).
SVB Leerink, at Medicenna's discretion and instruction, will use its commercially reasonable efforts to sell the common shares at prevailing market prices from time to time. No offers or sales of common shares will be made in Canada or through the facilities of the Toronto Stock Exchange. The ATM offering will be made by way of a prospectus supplement to the company's Canadian final base shelf prospectus, as amended, and the company's United States final base shelf prospectus, which is contained in the company's U.S. registration statement on Form F-10 (file No. 333-238905), dated July 28, 2020, and declared effective by the United States Securities and Exchange Commission on July 30, 2020.
The ATM prospectus supplement has been filed in Canada with the Ontario Securities Commission, as principal regulator, the British Columbia Securities Commission and the Alberta Securities Commission, and in the United States with the SEC. The TSX has conditionally approved the ATM offering and the Nasdaq has been notified of the ATM offering.
The company plans to use the net proceeds of the ATM offering, if any, for general corporate purposes including, but not limited, to working capital expenditures, research and development expenditures, and clinical trial expenditures.
The ATM offering will terminate upon the earlier of (a) the sale of $25-million (U.S.) of common shares subject to the sales agreement, (b) the termination of the sales agreement by SVB Leerink or the company, as permitted therein, or (c) Aug. 28, 2022.
Copies of the ATM prospectus supplement will be available upon request by contacting SVB Leerink LLC, attention: Syndicate Department, One Federal St., 37th floor, Boston, Mass., 02110, by telephone at 1-800-808-7525, extension 6132, or by e-mail at syndicate@sbvleerink.com. The ATM prospectus supplement (together with the related base shelf prospectus) is also available on the SEC's website. Before you invest, you should read the ATM prospectus supplement and the related base shelf prospectus and other documents that the company has filed with the SEC for more complete information about the company, the sales agreement and the ATM offering.
About Medicenna Therapeutics Corp.
Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 superkines, and first-in-class empowered cytokines (ECs) for the treatment of a broad range of cancers. Medicenna's long-acting IL2 superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity, and therefore preferentially stimulating cancer-killing effector T cells and NK cells when compared with competing IL-2 programs. It is anticipated that MDNA11 will be ready for the clinic in 2021. Medicenna's lead IL4-EC, MDNA55, has completed a phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained fast track and orphan drug status from the FDA and FDA/EMA (European Medicines Agency), respectively.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.
Posts
